{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:24Z","timestamp":1789726224631,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejphar.2025.178077","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:39:18Z","timestamp":1755614358000},"page":"178077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Post-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database"],"prefix":"10.1016","volume":"1005","author":[{"given":"Huqiang","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mixue","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2019e","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ejphar.2025.178077_bib1","doi-asserted-by":"crossref","first-page":"764","DOI":"10.7326\/M19-0085","article-title":"Fournier gangrene associated with sodium-glucose Cotransporter-2 inhibitors: a review of spontaneous postmarketing cases","volume":"170","author":"Bersoff-Matcha","year":"2019","journal-title":"Ann. Intern. Med."},{"issue":"15","key":"10.1016\/j.ejphar.2025.178077_bib2","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178077_bib3","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.ejphar.2025.178077_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003666","article-title":"Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors","volume":"11","author":"Chow","year":"2023","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1060028020951928","article-title":"Prevention and management of genital mycotic infections in the setting of sodium-glucose cotransporter 2 inhibitors","volume":"55","author":"Engelhardt","year":"2021","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178077_bib6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"2","key":"10.1016\/j.ejphar.2025.178077_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001856","article-title":"Real-world risk of hypoglycemia-related hospitalization in Japanese patients with type 2 diabetes using SGLT2 inhibitors: a nationwide cohort study","volume":"8","author":"Horii","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.ejphar.2025.178077_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose Cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system","volume":"2020","author":"Hu","year":"2020","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejphar.2025.178077_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.713192","article-title":"Adding sodium\u2013glucose Co-Transporter 2 inhibitors to sulfonylureas and risk of hypoglycemia: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Jiang","year":"2021","journal-title":"Front. Endocrinol."},{"issue":"3","key":"10.1016\/j.ejphar.2025.178077_bib10","first-page":"420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthc. Basel Switz."},{"issue":"Suppl. 7","key":"10.1016\/j.ejphar.2025.178077_bib11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/dom.15921","article-title":"Continuous ketone monitoring: exciting implications for clinical practice","volume":"26","author":"Kong","year":"2024","journal-title":"Diabetes Obes. Metabol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178077_bib12","first-page":"465","article-title":"The ketogenic effect of SGLT-2 inhibitors\u2014beneficial or harmful?","volume":"10","author":"Koutentakis","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178077_bib13","article-title":"Vitreoretinal traction syndrome, nitrituria and human epidermal growth factor receptor negative might occur in the aromatase-inhibitor anastrozole treatment","volume":"2024","author":"Li","year":"2024","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.178077_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.752440","article-title":"Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib15","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40265-018-0878-6","article-title":"Ertugliflozin: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib16","first-page":"144","article-title":"Pharmacovigilance of sodium-glucose Cotransporter-2 inhibitors for genital fungal infections and urinary tract infections: a review of the food and drug administration adverse event reporting system database","volume":"34","author":"Mohammad","year":"2018","journal-title":"J. Pharm. Technol. Jpt Off. Publ. Assoc. Pharm. Tech."},{"key":"10.1016\/j.ejphar.2025.178077_bib17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","article-title":"Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats","volume":"10","author":"Perry","year":"2019","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am. J. Kidney Dis."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178077_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US fDA's spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178077_bib20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12902-023-01464-6","article-title":"Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes","volume":"23","author":"Tanr\u0131verdi","year":"2023","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.ejphar.2025.178077_bib21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2337\/cd21-0015","article-title":"Sodium\u2013glucose cotransporter 2 inhibitor use associated with fournier's gangrene: a review of case reports and spontaneous post-marketing cases","volume":"40","author":"Tran","year":"2022","journal-title":"Clin. Diabetes"},{"issue":"2","key":"10.1016\/j.ejphar.2025.178077_bib22","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.xkme.2019.12.006","article-title":"SGLT2 inhibitor\u2013induced euglycemic diabetic ketoacidosis: a case report","volume":"2","author":"Wang","year":"2020","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1111\/andr.13533","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system events for sildenafil","volume":"12","author":"Wang","year":"2024","journal-title":"Andrology"},{"issue":"4","key":"10.1016\/j.ejphar.2025.178077_bib24","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178077_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.00190","article-title":"Prospect of sodium\u2013glucose Co-Transporter 2 inhibitors combined with insulin for the treatment of type 2 diabetes","volume":"11","author":"Yang","year":"2020","journal-title":"Front. Endocrinol."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178077_bib26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2023.2235267","article-title":"A real-world data analysis of acetylsalicylic acid in FDA adverse event reporting system (FAERS) database","volume":"19","author":"Zhao","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.ejphar.2025.178077_bib27","article-title":"A real-world disproportionality analysis of everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejphar.2025.178077_bib28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1080\/14740338.2024.2410436","article-title":"A real-world pharmacovigilance study using disproportionality analysis of United States food and drug administration adverse event reporting system events for vinca alkaloids: comparing vinorelbine and vincristine","volume":"23","author":"Zhong","year":"2024","journal-title":"Expet Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.ejphar.2025.178077_bib29","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am. J. Kidney Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299925008313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T20:44:43Z","timestamp":1758055483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299925008313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"alternative-id":["S0014299925008313"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178077","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-marketing safety profile of Ertugliflozin: Insights from a real-world pharmacovigilance analysis based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.178077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"178077"}}